Kymera Therapeutics (KYMR) to Release Earnings on Friday

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Friday, May 9th. Analysts expect the company to announce earnings of ($0.93) per share and revenue of $11.38 million for the quarter.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $7.39 million during the quarter, compared to analysts' expectations of $14.81 million. On average, analysts expect Kymera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kymera Therapeutics Stock Up 0.9 %

Shares of Kymera Therapeutics stock traded up $0.31 during trading on Tuesday, reaching $33.92. The company's stock had a trading volume of 59,778 shares, compared to its average volume of 554,510. Kymera Therapeutics has a 52-week low of $19.45 and a 52-week high of $53.27. The company has a market cap of $2.20 billion, a price-to-earnings ratio of -14.41 and a beta of 2.22. The firm's 50-day moving average is $29.80 and its two-hundred day moving average is $38.46.

Insider Activity

In related news, insider Ellen Chiniara sold 2,241 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares of the company's stock, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock worth $324,567 over the last three months. Corporate insiders own 15.82% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Citigroup assumed coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective on the stock. HC Wainwright raised their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Finally, Stephens restated an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $56.36.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.